Microalgal Strain Stress Tolerance Patents: Leaders & Trends 2026
- Concentrated at the top. the leading assignee alone accounts for 22 of 112 records, and the top 5 combined hold 58.0% of all records in scope.
- Filing is still accelerating, not cooling. growth ran +133% from 2021 (3 filings) to 2024 (7 filings), the most recent year that can be read as complete.
- Fermentation claims dominate over cultivation. C12P fermentation and enzymatic synthesis appears in 56.3% of records, well ahead of feed (A23K, 28.6%) and fuel (C10L, 19.6%) end uses.
Filing growth compares 2021 (3 records) with 2024 (7) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 112 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
Stress tolerance in microalgal strains — resistance to solvent exposure, low pH, osmotic shock, oxidative damage, heat shock and loss of membrane stability — sits at the intersection of strain engineering and downstream processing. Patents in this space typically claim a tolerant microalgal cell or recombinant microalga alongside a cultivation, extraction or fermentation method that depends on that tolerance holding up under industrial conditions. The scope here spans 112 published records filed or published between 2015 and the mid-2026 cut-off, indexed under microorganism, fermentation and assay-related IPC classes.
Because publication lags filing by roughly 18 months, the 2025 and 2026 figures in any trend chart are undercounts, not a real slowdown. Read the growth signal through 2024, the last year with a reasonably complete filing record.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trends and technology composition
The filing curve and the IPC mix together show a field still building strain-engineering claims on top of an established fermentation base, with feed and fuel applications trailing as the largest downstream markets.
Filing trend, 2017–2026
Filings rose from 5 in 2017 to a peak of 9 in 2022, before the +133% run from 3 filings in 2021 to 7 in 2024. Treat 2025 and 2026 as incomplete rather than declining.
Technology composition by IPC subclass
C12N (microorganisms and genetic engineering) touches 99.1% of records, effectively table stakes for this search string. The differentiation sits below it: C12P fermentation methods reach 56.3% of records, while feed (A23K), fuel (C10L) and food (A23L) end-use claims each cover a much smaller, more contestable slice.
Shares are the percentage of the 112 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Microalgal Strain Stress Tolerance with Eureka
This page is one run against one query. Ask Eureka your own question about microalgal strain stress tolerance and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records in this space
Heterotrophic production methods for microbial biomass and bioproducts (US20180002711A1)
The invention pertains to a method for synthesizing a product of interest by culturing a microalgal cell producing the product of interest in the dark in a culture medium comprising an organic acid as a fixed carbon source, wherein the microalgal cell is a facultative heterotroph. The product of interest can be a microalgal biomass, a pigment, terpene, recombinant molecule, biogas, or a precursor thereof. In an embodiment, the culture medium comprises urea as a primary source of nitrogen. In one embodiment, the microalgal cell belongs to the order Chlamydomonadales.Filed by Kuehnle AgroSystems; abstract shortened for length.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20110092726A1 | System for cultivation and processing of microorganisms, processing of products therefrom, and processing in … | 232 |
| 2 | WO2010063032A2 | Production of tailored oils in heterotrophic microorganisms | 201 |
| 3 | WO2010063031A2 | Manufacturing of tailored oils in recombinant heterotrophic microorganisms | 172 |
| 4 | US20100151112A1 | Novel Triglyceride and Fuel Compositions | 165 |
| 5 | US7935515B2 | Recombinant microalgae cells producing novel oils | 122 |
| 6 | US8187860B2 | Recombinant microalgae cells producing novel oils | 95 |
| 7 | US20100151539A1 | Recombinant Microalgae Cells Producing Novel Oils | 76 |
| 8 | US20100267122A1 | Microalgae cultivation in a wastewater dominated by carpet mill effluents for biofuel applications | 68 |
| 9 | US8697427B2 | Recombinant microalgae cells producing novel oils | 46 |
| 10 | US20110165634A1 | Renewable chemical production from novel fatty acid feedstocks | 38 |
Citation counts favour older, earlier-filed records inside this corpus — treat them as a measure of influence on later filers, not of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers imply for a filing decision
Three patterns matter more than the raw counts: where claim density already sits, where growth is real versus where it is an artefact of publication lag, and which end-use application is still lightly claimed.
A small group holds the core claim space
The leading assignee alone holds 22 of 112 records, and the top 5 combined control 58.0% of everything in scope. A new entrant filing a broad tolerant-strain claim is filing into ground five parties have already staked out.
Momentum is real through 2024, not beyond it
Filings grew from 3 in 2021 to 7 in 2024 and peaked at 9 in 2022. Because publication lags filing by about 18 months, the apparent dip in 2025-2026 should not be read as the field cooling.
Feed and fuel are claimed far more than pharma
A23K animal feed reaches 28.6% of records and C10L fuel 19.6%, while A61K medicinal preparations sits at just 13.4% and A23L food and beverage at 11.6%. Stress-tolerant strain claims aimed at therapeutic or nutraceutical output are comparatively thin.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to microalgal strain stress tolerance, with the prior art for and against each one.
The assignee landscape
Forty companies make up the full ranked list this dataset returns. Filing is not evenly spread: a leader with 22 records sits well ahead of a fifth-place holder at 6 and a tenth-place holder at 4, and momentum among several of the largest historical filers has gone quiet in the most recent year.
One filer set the early claim map
The leading assignee's 22 records establish a strong baseline across fermentation and cultivation claims that later entrants have had to file around rather than through.
Collaboration is limited and concentrated
Only 8 co-assignee pairs appear across the dataset, and the strongest repeated pairings all cluster around a single historical filer and its named inventors, rather than spreading across multiple corporate partnerships.
Several large early filers have stopped filing
A number of the assignees with the deepest historical portfolios in this space show zero filings in the latest year, including one with a -100% year-on-year change. That does not necessarily mean exit — some of these entities have been through corporate restructuring — but it does mean their portfolios are now static targets rather than moving ones.
| Assignee | Recent year | YoY |
|---|---|---|
| Research Institute at Nationwide Children's Hospital | 0 | -100% |
| Solazyme, Inc. | 0 | — |
| TransAlgae Israel Ltd. | 0 | — |
| TerraVia Holdings, Inc. | 0 | — |
| Hutan Bio Ltd. | 0 | — |
| Corbion Biotech, Inc. | 0 | — |
| Murdoch University | 0 | — |
| Japan Science and Technology Agency | 0 | — |
Where to take this analysis
The dataset points to three practical next steps for a team deciding whether and where to file.
Map claims against the leader's portfolio
With 58.0% of records held by five parties, a new filing needs to be checked claim-by-claim against the leading assignee's fermentation and cultivation scope before drafting.
Run a portfolio comparisonWatch the 2024-2025 filing gap close
Publication lag means 2025-2026 numbers will keep rising as more records surface. Re-check the trend in six months rather than treating the current dip as real.
Track filing trendsTest the under-claimed application branches
Medicinal and food-grade applications of stress-tolerant strains are lightly claimed relative to feed and fuel. A first claim there faces a thinner prior-art wall.
Explore white space with EurekaCommon questions on this landscape
One assignee leads the ranked list with 22 of the 112 records in scope, well ahead of the fifth-ranked filer at 6 records and the tenth-ranked filer at 4. The top 5 assignees combined hold 58.0% of all records, and the top 10 combined hold 77.7%. This means the field is concentrated at the top but still has a long tail of smaller filers below the leading group, rather than being a two-party contest.
Filings grew from 3 in 2021 to 7 in 2024, a +133% increase over that three-year span, with a peak of 9 filings in 2022. The apparent drop-off in 2025 and 2026 is a publication-lag artefact, not a real slowdown: patent publication typically trails filing by around 18 months, so the most recent one to two years are always undercounted. Anyone tracking this field should treat 2024 as the last reliably complete year.
Nearly all records (99.1%) touch C12N, the broad microorganism and genetic-engineering class, which functions as a baseline rather than a differentiator. The real technical split shows up further down: C12P fermentation and enzymatic synthesis methods appear in 56.3% of records, while downstream applications split across animal feed (A23K, 28.6%), fuel (C10L, 19.6%), specialty chemicals (C07C, 14.3%), medicinal preparations (A61K, 13.4%) and food or beverage uses (A23L, 11.6%).
The application-side classes are the clearest gap: medicinal preparations (A61K) sit at just 13.4% of records and food/beverage uses (A23L) at 11.6%, both well below the feed and fuel end uses that dominate current claims. Specific under-claimed combinations include acid-tolerant strains paired with food-grade output claims, osmotic-stress screening assays under C12Q1/04, and heat-shock tolerance framed for medicinal rather than industrial biomass. These are areas where the core strain-engineering claims are already crowded but the application-specific claim layer is thin.
This filing, from Kuehnle AgroSystems, claims a method of culturing a facultative heterotroph microalgal cell in the dark using an organic acid as a fixed carbon source, including embodiments using urea as the primary nitrogen source and cells from the order Chlamydomonadales. It reads narrowly on dark heterotrophic culturing with an organic-acid carbon source, so processes relying on photoautotrophic or mixotrophic culturing, or on carbon sources outside that organic-acid framing, are less likely to fall within its literal claims. Anyone designing a dark-culture process with an organic acid feedstock should review its full claim set before proceeding.
Research Microalgal Strain Stress Tolerance in depth with Eureka
Go past this page: query the whole microalgal strain stress tolerance corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.